Pharsight

Harvoni generic

Harvoni is an antiviral drug owned by Gilead Sciences Inc. It contains the active ingredients Ledipasvir and Sofosbuvir. Harvoni was granted its first marketing authorization on 28 August, 2019 and holds a total of 33 patents, none of which have expired as of yet.

When will Harvoni generic be available?

The generic versions of Harvoni are slated for release after 30 July, 2034. This is due to the expiry of the drug's last patent, particularly US10039779 titled 'Combination formulation of two antiviral compounds' on that date.

Harvoni uses

Harvoni can be used for the treatment of Hepatitis C. It is particularly effective in treating genotype 1, 4, 5, or 6 chronic Hepatitis C virus (HCV) infections, even in patients receiving treatment for the first time. The drug's treatment duration spans 8 weeks.

Harvoni patent expiration

The latest patent of Harvoni, labeled 'Combination formulation of two antiviral compounds', is going to expire on 30th July, 2034 and is, therefore, the main determinant of the Harvoni generic release date. Other notable patents include US9284342 titled 'Nucleoside phosphoramidates', set to expire in March 2031, and US9393256, 'Methods for treating HCV', expiring in September 2032. Below are the details of the patents:

EPO Oppostions filed on Harvoni

Litigations filed on Harvoni

Harvoni dosage

Want to ask something?